Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease.

Huichalaf CH, Al-Ramahi I, Park KW, Grunke SD, Lu N, de Haro M, El-Zein K, Gallego-Flores T, Perez AM, Jung SY, Botas J, Zoghbi HY, Jankowsky JL.

Hum Mol Genet. 2019 Jun 15;28(12):2014-2029. doi: 10.1093/hmg/ddz034.

PMID:
30753434
2.

A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.

Rousseaux MWC, Vázquez-Vélez GE, Al-Ramahi I, Jeong HH, Bajić A, Revelli JP, Ye H, Phan ET, Deger JM, Perez AM, Kim JY, Lavery LA, Xu Q, Li MZ, Kang H, Kim JJ, Shulman JM, Westbrook TF, Elledge SJ, Liu Z, Botas J, Zoghbi HY.

J Neurosci. 2018 Oct 24;38(43):9286-9301. doi: 10.1523/JNEUROSCI.0254-18.2018. Epub 2018 Sep 24.

3.

High-Throughput Functional Analysis Distinguishes Pathogenic, Nonpathogenic, and Compensatory Transcriptional Changes in Neurodegeneration.

Al-Ramahi I, Lu B, Di Paola S, Pang K, de Haro M, Peluso I, Gallego-Flores T, Malik NT, Erikson K, Bleiberg BA, Avalos M, Fan G, Rivers LE, Laitman AM, Diaz-García JR, Hild M, Palacino J, Liu Z, Medina DL, Botas J.

Cell Syst. 2018 Jul 25;7(1):28-40.e4. doi: 10.1016/j.cels.2018.05.010. Epub 2018 Jun 20.

4.

Inhibition of PIP4Kγ ameliorates the pathological effects of mutant huntingtin protein.

Al-Ramahi I, Giridharan SSP, Chen YC, Patnaik S, Safren N, Hasegawa J, de Haro M, Wagner Gee AK, Titus SA, Jeong H, Clarke J, Krainc D, Zheng W, Irvine RF, Barmada S, Ferrer M, Southall N, Weisman LS, Botas J, Marugan JJ.

Elife. 2017 Dec 26;6. pii: e29123. doi: 10.7554/eLife.29123.

5.

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau.

Rousseaux MW, de Haro M, Lasagna-Reeves CA, De Maio A, Park J, Jafar-Nejad P, Al-Ramahi I, Sharma A, See L, Lu N, Vilanova-Velez L, Klisch TJ, Westbrook TF, Troncoso JC, Botas J, Zoghbi HY.

Elife. 2016 Oct 25;5. pii: e19809. doi: 10.7554/eLife.19809.

6.

Reduction of Nuak1 Decreases Tau and Reverses Phenotypes in a Tauopathy Mouse Model.

Lasagna-Reeves CA, de Haro M, Hao S, Park J, Rousseaux MW, Al-Ramahi I, Jafar-Nejad P, Vilanova-Velez L, See L, De Maio A, Nitschke L, Wu Z, Troncoso JC, Westbrook TF, Tang J, Botas J, Zoghbi HY.

Neuron. 2016 Oct 19;92(2):407-418. doi: 10.1016/j.neuron.2016.09.022. Epub 2016 Oct 6.

7.

Metal Homeostasis Regulators Suppress FRDA Phenotypes in a Drosophila Model of the Disease.

Soriano S, Calap-Quintana P, Llorens JV, Al-Ramahi I, Gutiérrez L, Martínez-Sebastián MJ, Botas J, Moltó MD.

PLoS One. 2016 Jul 19;11(7):e0159209. doi: 10.1371/journal.pone.0159209. eCollection 2016.

8.

Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice.

Langfelder P, Cantle JP, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, Lu XH, Ramos EM, El-Zein K, Zhao Y, Deverasetty S, Tebbe A, Schaab C, Lavery DJ, Howland D, Kwak S, Botas J, Aaronson JS, Rosinski J, Coppola G, Horvath S, Yang XW.

Nat Neurosci. 2016 Apr;19(4):623-33. doi: 10.1038/nn.4256. Epub 2016 Feb 22.

9.

Huntingtin proteolysis releases non-polyQ fragments that cause toxicity through dynamin 1 dysregulation.

El-Daher MT, Hangen E, Bruyère J, Poizat G, Al-Ramahi I, Pardo R, Bourg N, Souquere S, Mayet C, Pierron G, Lévêque-Fort S, Botas J, Humbert S, Saudou F.

EMBO J. 2015 Sep 2;34(17):2255-71. doi: 10.15252/embj.201490808. Epub 2015 Jul 12.

10.

TORC1 Inhibition by Rapamycin Promotes Antioxidant Defences in a Drosophila Model of Friedreich's Ataxia.

Calap-Quintana P, Soriano S, Llorens JV, Al-Ramahi I, Botas J, Moltó MD, Martínez-Sebastián MJ.

PLoS One. 2015 Jul 9;10(7):e0132376. doi: 10.1371/journal.pone.0132376. eCollection 2015.

11.

A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity.

Yao Y, Cui X, Al-Ramahi I, Sun X, Li B, Hou J, Difiglia M, Palacino J, Wu ZY, Ma L, Botas J, Lu B.

Elife. 2015 Mar 4;4. doi: 10.7554/eLife.05449.

12.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
13.

Micronucleus frequency among Iraqi thyroid disorder patients.

AlFaisal AH, Al-Ramahi IJ, Abdul-Hassan IA.

Comp Clin Path. 2012 Dec 28;23:683-688. eCollection 2014.

14.

Detection of heterozygous c.1708C>T and c.1978C>G thyroid peroxidase (TPO) mutations in Iraqi patients with toxic and nontoxic goiter.

Al-Faisal AH, Al-Ramahi IJ, Abudl-Hassan IA, Hamdan AT, Barusrux S.

Comp Clin Path. 2012 Aug 8;23:69-75. eCollection 2014.

15.

RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1.

Park J, Al-Ramahi I, Tan Q, Mollema N, Diaz-Garcia JR, Gallego-Flores T, Lu HC, Lagalwar S, Duvick L, Kang H, Lee Y, Jafar-Nejad P, Sayegh LS, Richman R, Liu X, Gao Y, Shaw CA, Arthur JSC, Orr HT, Westbrook TF, Botas J, Zoghbi HY.

Nature. 2013 Jun 20;498(7454):325-331. doi: 10.1038/nature12204. Epub 2013 May 29.

16.

Smaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.

de Haro M, Al-Ramahi I, Jones KR, Holth JK, Timchenko LT, Botas J.

PLoS Genet. 2013 Apr;9(4):e1003445. doi: 10.1371/journal.pgen.1003445. Epub 2013 Apr 18.

17.

Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.

Lu B, Al-Ramahi I, Valencia A, Wang Q, Berenshteyn F, Yang H, Gallego-Flores T, Ichcho S, Lacoste A, Hild M, Difiglia M, Botas J, Palacino J.

Nat Neurosci. 2013 May;16(5):562-70. doi: 10.1038/nn.3367. Epub 2013 Mar 24.

PMID:
23525043
18.

A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease.

Miller JP, Yates BE, Al-Ramahi I, Berman AE, Sanhueza M, Kim E, de Haro M, DeGiacomo F, Torcassi C, Holcomb J, Gafni J, Mooney SD, Botas J, Ellerby LM, Hughes RE.

PLoS Genet. 2012;8(11):e1003042. doi: 10.1371/journal.pgen.1003042. Epub 2012 Nov 29.

19.

Network organization of the huntingtin proteomic interactome in mammalian brain.

Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, Botas J, Coppola G, Horvath S, Loo JA, Yang XW.

Neuron. 2012 Jul 12;75(1):41-57. doi: 10.1016/j.neuron.2012.05.024.

20.

Inhibition of lipid signaling enzyme diacylglycerol kinase epsilon attenuates mutant huntingtin toxicity.

Zhang N, Li B, Al-Ramahi I, Cong X, Held JM, Kim E, Botas J, Gibson BW, Ellerby LM.

J Biol Chem. 2012 Jun 15;287(25):21204-13. doi: 10.1074/jbc.M111.321661. Epub 2012 Apr 16.

21.

Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease.

Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, Zhang N, Kim E, Sanhueza M, Torcassi C, Kwak S, Botas J, Hughes RE, Ellerby LM.

Neuron. 2010 Jul 29;67(2):199-212. doi: 10.1016/j.neuron.2010.06.021.

22.

Detailed analysis of leucokinin-expressing neurons and their candidate functions in the Drosophila nervous system.

de Haro M, Al-Ramahi I, Benito-Sipos J, López-Arias B, Dorado B, Veenstra JA, Herrero P.

Cell Tissue Res. 2010 Feb;339(2):321-36. doi: 10.1007/s00441-009-0890-y. Epub 2009 Nov 26.

PMID:
19941006
23.

dAtaxin-2 mediates expanded Ataxin-1-induced neurodegeneration in a Drosophila model of SCA1.

Al-Ramahi I, Pérez AM, Lim J, Zhang M, Sorensen R, de Haro M, Branco J, Pulst SM, Zoghbi HY, Botas J.

PLoS Genet. 2007 Dec 28;3(12):e234. doi: 10.1371/journal.pgen.0030234. Epub 2007 Nov 16.

24.

Comparative analysis of genetic modifiers in Drosophila points to common and distinct mechanisms of pathogenesis among polyglutamine diseases.

Branco J, Al-Ramahi I, Ukani L, Pérez AM, Fernandez-Funez P, Rincón-Limas D, Botas J.

Hum Mol Genet. 2008 Feb 1;17(3):376-90. Epub 2007 Nov 5.

PMID:
17984172
25.

CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation.

Al-Ramahi I, Lam YC, Chen HK, de Gouyon B, Zhang M, Pérez AM, Branco J, de Haro M, Patterson C, Zoghbi HY, Botas J.

J Biol Chem. 2006 Sep 8;281(36):26714-24. Epub 2006 Jul 10.

26.

MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1.

de Haro M, Al-Ramahi I, De Gouyon B, Ukani L, Rosa A, Faustino NA, Ashizawa T, Cooper TA, Botas J.

Hum Mol Genet. 2006 Jul 1;15(13):2138-45. Epub 2006 May 24.

PMID:
16723374

Supplemental Content

Loading ...
Support Center